Javascript must be enabled to continue!
Psychometric evaluation and medication usage pattern in Covid-19 patients: A retrospective study
View through CrossRef
Aim and objective: Assessing and evaluating Psychometric and medication usage patterns in COVID-19 patients retrospective study. assessing the post-COVID-19 subjects, evaluating the drug report in a post-COVID-19 subject, and measuring psychological status. Evaluation of the serious adverse reaction on the south-Indian population of the post-COVID-19 subject. Methodology: In which 150 subjects were taken and 127 participated. Inclusion criteria COVID-19 subject with adult age group, Patient was admitted and discharged before 3 months and above for COVID-19 with positive RT-PCR Report exclusion criteria patient who is recently tested for COVID-19 and pregnant women and lactating women and who are below the adult age group. Where follow-up is done to assess the psychometric evaluation it is a retrospective study with follow-up. Result: 127 patients were analyzed, in that there are 49 female subjects and 78 male subjects, therefore a total of 1 of 27 patients. The vaccination status of the subjects was analyzed with the data depleted. In that, 118 subjects were affected by Covid-19 before vaccination and only 9 subjects were affected after vaccination. In this pandemic, many subjects were Mentally stressed by their Neighborhood and 32 subjects were not stressed. The generalized anxiety disorder score shows that 15 subjects were currently experiencing low risk, 58 subjects were in the mild range, 32 subjects were in the moderate range and 22 subjects were in the mild range. The discharge medication data shows Vitamin C and Multivitamin tablets were prescribed nearly for 114-116 subjects, secondly, Pantoprazole was prescribed for 96 subjects, thirdly Prednisolone was prescribed for 96 subjects and Paracetamol was prescribed for 68 subjects. At last, other drugs are prescribed according to the Co-Morbidities of the subject. Conclusion: 127 patients were analyzed, in that there are 49 female subjects and 78 male subjects. 85 subjects were affected between ages 18-60 years whereas 42 subjects were affected above the age of 60 years. The vaccination and the non-vaccination status report shows that non-vaccinated people are affected more than vaccinated people. The Generalized Anxiety Disorder (GAD) category depletes that the patients experienced mild to moderate levels of anxiety. The Pearson Chi-square value is 23.271 and the P value is <0.001. This shows the association between anxiety with COVID-19 patients. The Major Depression Inventory (MDI) score depletes severe depression which might be due to the pandemic situation, economic situation, and local restrictions. The Pearson Chi-square value is 70.572 and the P-value is <0.001 showing that there is an association between depression and COVID in patients. This shows that post-COVID-19 affected subjects are experiencing Psychological effects in many terms. These Psychological effects are due to COVID-19 and the intake of Steroids during the treatment and after discharge.
Title: Psychometric evaluation and medication usage pattern in Covid-19 patients: A retrospective study
Description:
Aim and objective: Assessing and evaluating Psychometric and medication usage patterns in COVID-19 patients retrospective study.
assessing the post-COVID-19 subjects, evaluating the drug report in a post-COVID-19 subject, and measuring psychological status.
Evaluation of the serious adverse reaction on the south-Indian population of the post-COVID-19 subject.
Methodology: In which 150 subjects were taken and 127 participated.
Inclusion criteria COVID-19 subject with adult age group, Patient was admitted and discharged before 3 months and above for COVID-19 with positive RT-PCR Report exclusion criteria patient who is recently tested for COVID-19 and pregnant women and lactating women and who are below the adult age group.
Where follow-up is done to assess the psychometric evaluation it is a retrospective study with follow-up.
Result: 127 patients were analyzed, in that there are 49 female subjects and 78 male subjects, therefore a total of 1 of 27 patients.
The vaccination status of the subjects was analyzed with the data depleted.
In that, 118 subjects were affected by Covid-19 before vaccination and only 9 subjects were affected after vaccination.
In this pandemic, many subjects were Mentally stressed by their Neighborhood and 32 subjects were not stressed.
The generalized anxiety disorder score shows that 15 subjects were currently experiencing low risk, 58 subjects were in the mild range, 32 subjects were in the moderate range and 22 subjects were in the mild range.
The discharge medication data shows Vitamin C and Multivitamin tablets were prescribed nearly for 114-116 subjects, secondly, Pantoprazole was prescribed for 96 subjects, thirdly Prednisolone was prescribed for 96 subjects and Paracetamol was prescribed for 68 subjects.
At last, other drugs are prescribed according to the Co-Morbidities of the subject.
Conclusion: 127 patients were analyzed, in that there are 49 female subjects and 78 male subjects.
85 subjects were affected between ages 18-60 years whereas 42 subjects were affected above the age of 60 years.
The vaccination and the non-vaccination status report shows that non-vaccinated people are affected more than vaccinated people.
The Generalized Anxiety Disorder (GAD) category depletes that the patients experienced mild to moderate levels of anxiety.
The Pearson Chi-square value is 23.
271 and the P value is <0.
001.
This shows the association between anxiety with COVID-19 patients.
The Major Depression Inventory (MDI) score depletes severe depression which might be due to the pandemic situation, economic situation, and local restrictions.
The Pearson Chi-square value is 70.
572 and the P-value is <0.
001 showing that there is an association between depression and COVID in patients.
This shows that post-COVID-19 affected subjects are experiencing Psychological effects in many terms.
These Psychological effects are due to COVID-19 and the intake of Steroids during the treatment and after discharge.
Related Results
NICU Medication Errors: Describing the Cause and Nature of Medication Errors in a NICU in Qatar
NICU Medication Errors: Describing the Cause and Nature of Medication Errors in a NICU in Qatar
IntroductionA medication error can be defined as “any error occurring in the medication use process” and focuses on problems with the delivery of medication to a patient [1]. Medic...
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
Medication beliefs and adherence– exploring pharmaceutical care interventions and patients’ experiences
Medication beliefs and adherence– exploring pharmaceutical care interventions and patients’ experiences
<strong>Background</strong>
In pharmaceutical care, healthcare professionals collaborate with patients to optimise medication therapy. For patients usin...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Abstract 2233: Biobehavioral Factors and Heart Failure Medication Adherence
Abstract 2233: Biobehavioral Factors and Heart Failure Medication Adherence
Background:
Medication adherence in heart failure (HF) patients reduces hospitalizations and improves outcomes, yet it is variable. This study evaluated adherence rates...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
1
Jose F.
Tellez‐Zenteno,
1
Scott B.
Patten, and
1
Samuel
Wiebe
...

